Fractyl Health, Inc. (GUTS)

6.19 -0.03 (-0.48%) At close: 04:00PM EDT

Fractyl Health, Inc.

3 Van de Graaff Drive
Suite 200
Burlington, MA 01803
United States
781-902-8800
https://fractyl.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 102

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Harith Rajagopalan M.D., Ph.D.	Co-Founder, CEO & Director	863.77k	N/A	1977
Mr. Jay D. Caplan BSEE, MBA	Co-Founder, Chief Product Officer & President	555.19k	N/A	1962
Dr. Timothy J. Kieffer Ph.D.	Chief Scientific Officer	140.64k	N/A	1967
Ms. Lisa A. Davidson MBA	CFO & Treasurer	N/A	N/A	1967
Ms. Sarah S. Toomey Esq.	General Counsel & Corporate Secretary	479.36k	N/A	1975
Dr. Helmut Giersiefen	Head of Business Development	619.17k	N/A	N/A
Mr. Adrian Kimber	Chief Commercial Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Corporate governance

Fractyl Health, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.